Pharmacological therapy for acute pancreatitis: Where are we now? Where are we going?

Minerva Gastroenterologica e Dietologica

Volumn 58, Issue 4, 2012, Pages 365-375

  Easler, J J ^a   Mounzer, R ^a   Papachristou, G I ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Drug therapy; Octreotide; Pancreatitis; Protease inhibitors

Indexed keywords

ACETYLCYSTEINE; ACTIVATED PROTEIN C; ALANYLGLUTAMINE; ANTIBIOTIC AGENT; ANTIOXIDANT; APROTININ; ASCORBIC ACID; DROTRECOGIN; GABEXATE MESILATE; GLUTAMINE; IMIPENEM; IMMUNOMODULATING AGENT; INDOMETACIN; LEXIPAFANT; NAFAMSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PLACEBO; PROBIOTIC AGENT; PROTEINASE INHIBITOR; S ADENOSYLMETHIONINE; SELENIUM; SOMATOSTATIN; STOMACH SECRETION INHIBITOR;

ACUTE PANCREATITIS; ANTIBIOTIC THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERIC FEEDING; FLUID RESUSCITATION; HUMAN; MULTIPLE ORGAN FAILURE; NONHUMAN; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PANCREAS NECROSIS; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL DRAINAGE;

ACUTE DISEASE; ALGORITHMS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MONITORING, PHYSIOLOGIC; OCTREOTIDE; PANCREATITIS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROTEASE INHIBITORS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84873508189     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ et al. Burden of Gastrointestinal Disease in the United States: 2012 Update. Gastroenterology 2012 [Epub ahead of print].
2. Chen CC, Wang SS, Lee FY. Action of antiproteases on the inflammatory response in acute pancreatitis. JOP 2007;8(4 Suppl):488-94.
3. Bang UC, Semb S, Nojgaard C, Bendtsen F. Pharmacological approach to acute pancreatitis. World J Gastroenterol 2008;14:2968-76.
4. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. Gastroenterology 2007;132:1127-51. (Pubitemid 46440879)
5. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006;354:2142-50.
6. Papachristou GI, Clermont G, Sharma A, Yadav D, Whitcomb DC. Risk and markers of severe acute pancreatitis. Gastroenterol Clin North Am 2007;36:277-96, viii. (Pubitemid 46803185)
7. Kylanpaa ML, Repo H, Puolakkainen PA. Inflammation and immunosuppression in severe acute pancreatitis. World J Gastroenterol 2010;16:2867-72.
8. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000;47:546-52.
9. Lai EC, Mok FP, Tan ES, Lo CM, Fan ST, You KT et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med 1992;326:1582-6.
10. Petrov MS, van Santvoort HC, Besselink MG, van der Heijden GJ, van Erpecum KJ, Gooszen HG. Early endoscopic retrograde cholangiopancreatography versus conservative management in acute biliary pancreatitis without cholangitis: a meta-analysis of randomized trials. Ann Surg 2008;247:250-7. (Pubitemid 351156766)
11. Nguyen GC, Rosenberg M, Chong RY, Chong CA. Early cholecystectomy and ERCP are associated with reduced readmissions for acute biliary pancreatitis: a nationwide, population-based study. Gastrointest Endosc 2012;75:47-55.
12. Greenberg R, Haddad R, Kashtan H, Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med 2000;135:112-21. (Pubitemid 30105069)
13. Durr HK, Maroske D, Zelder O, Bode JC. Glucagon therapy in acute pancreatitis. Report of a double-blind trial. Gut. 1978;19:175-9. (Pubitemid 8318427)
14. Cameron JL, Mehigan D, Zuidema GD. Evaluation of atropine in acute pancreatitis. Surg Gynecol Obstet. 1979;148:206-8. (Pubitemid 9132187)
15. Goebell H, Ammann R, Herfarth C, Horn J, Hotz J, Knoblauch M et al. A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis. Scand J Gastroenterol. 1979;14:881-9. (Pubitemid 10161403)
16. Limberg B, Kommerell B. Treatment of acute pancreatitis with somatostatin. N Engl J Med. 1980;303:284. (Pubitemid 10092796)
17. Gjorup I, Roikjaer O, Andersen B, Burcharth F, Hovendal C, Pedersen SA et al. A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynecol Obstet. 1992;175:397-400.
18. Choi TK, Mok F, Zhan WH, Fan ST, Lai EC, Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomised controlled trial. Gut. 1989;30:223-7. (Pubitemid 19058876)
19. Luengo L, Vicente V, Gris F, Coronas JM, Escuder J, Ramon Gomez J et al. Influence of somatostatin in the evolution of acute pancreatitis. A prospective randomized study. Int J Pancreatol. 1994;15:139-44. (Pubitemid 24149754)
20. Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther. 1998;12:237-45. (Pubitemid 28160018)
21. Beechey-Newman N. Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity. Dig Dis Sci. 1993;38:644-7. (Pubitemid 23121270)
22. Paran H, Mayo A, Paran D, Neufeld D, Shwartz I, Zissin R et al. Octreotide treatment in patients with severe acute pancreatitis. Dig Dis Sci 2000;45:2247-51. (Pubitemid 32060401)
23. McKay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol. 1997;21:13-9. (Pubitemid 27184639)
24. Binder M, Uhl W, Friess H, Malfertheiner P, Buchler MW. Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion. 1994;55 Suppl 1:20-3. (Pubitemid 24020274)
25. Uhl W, Buchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45:97-104. (Pubitemid 29301852)
26. Heinrich S, Schafer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg 2006;243:154-68. (Pubitemid 43185433)
27. Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg. 1974;61:177-82.
28. Berling R, Genell S, Ohlsson K. High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: a double-blind randomized multi-center trial. J Gastroenterol. 1994;29:479-85. (Pubitemid 24262718)
29. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study. Int J Pancreatol. 1993;14:117-24. (Pubitemid 23326230)
30. Smith M, Kocher HM, Hunt BJ. Aprotinin in severe acute pancreatitis. Int J Clin Pract 2010;64:84-92.
31. Chen HM, Shyr MH, Chen MF. Gabexate mesilate improves pancreatic microcirculation and reduces lung edema in a rat model of acute pancreatitis. J Formos Med Assoc. 1997;96:704-9.
32. Freise J. [Therapy of acute pancreatitis with a synthetic protease and phospholipase A2 inhibitor gabexate mesilate]. Fortschr Med. 1983;101(31-32):1432-6.
33. Freise J, Melzer P, Schmidt FW, Horbach L. [Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients]. Z Gastroenterol. 1986;24:200-11.
34. Kitagawa M, Hayakawa T. Antiproteases in the treatment of acute pancreatitis. JOP 2007;8(4 Suppl):518-25. (Pubitemid 47263694)
35. Piascik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J et al. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas 2010;39:863-7.
36. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996;171:394-8. (Pubitemid 26105206)
37. Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 2004;28:369-73. (Pubitemid 38509739)
38. Takeda K, Yamauchi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S. Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatology 2001;1:668-73. (Pubitemid 33674965)
39. Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T et al. Treatment strategy against infection: clinical outcome of continuous regional arterial infusion, enteral nutrition, and surgery in severe acute pancreatitis. J Gastroenterol 2007;42:681-9. (Pubitemid 47278694)
40. Radenkovic D, Bajec D, Karamarkovic A, Stefanovic B, Milic N, Ignjatovic S et al. Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas 2004;29:152-6. (Pubitemid 38971805)
41. Jamdar S, Siriwardena AK. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis. Crit Care 2005;9:321-2. (Pubitemid 41136264)
42. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. (Pubitemid 32204987)
43. Yamanel L, Mas MR, Comert B, Isik AT, Aydin S, Mas N et al. The effect of activated protein C on experimental acute necrotizing pancreatitis. Crit Care 2005;9:R184-90.
44. Chen P, Zhang Y, Qiao M, Yuan Y. Activated protein C, an anticoagulant polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases. J Gastroenterol 2007;42:887-96. (Pubitemid 350142769)
45. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005;33:368-72. (Pubitemid 40216551)
46. Machala W, Wachowicz N, Komorowska A, Gaszynski W. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis-two case studies. Med Sci Monit 2004;10:CS31-6. (Pubitemid 38988181)
47. Pettila V, Kyhala L, Kylanpaa ML, Leppaniemi A, Tallgren M, Markkola A et al. APCAP - activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care 2010;14:R139.
48. Camussi G, Aglietta M, Malavasi F, Tetta C, Piacibello W, Sanavio F et al. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 1983;131:2397-403. (Pubitemid 14227442)
49. Camussi G, Tetta C, Coda R, Benveniste J. Release of platelet-activating factor in human pathology. I. Evidence for the occurrence of basophil degranulation and release of platelet-activating factor in systemic lupus erythematosus. Lab Invest 1981;44:241-51. (Pubitemid 11143379)
50. Chignard M, Le Couedic JP, Tence M, Vargaftig BB, Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature 1979;279:799-800.
51. Hanahan DJ. Platelet activating factor: a biologically active phosphoglyceride. Annu Rev Biochem 1986;55:483-509. (Pubitemid 16070778)
52. Emanuelli G, Montrucchio G, Gaia E, Dughera L, Corvetti G, Gubetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol 1989;134:315-26. (Pubitemid 19063887)
53. Kald B, Kald A, Ihse I, Tagesson C. Release of platelet-activating factor in acute experimental pancreatitis. Pancreas 1993;8:440-2. (Pubitemid 23183286)
54. Konturek SJ, Dembinski A, Konturek PJ, Warzecha Z, Jaworek J, Gustaw P et al. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut 1992;33:1268-74.
55. Formela LJ, Wood LM, Whittaker M, Kingsnorth AN. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg 1994;81:1783-5. (Pubitemid 24372370)
56. Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995;82:1414-20.
57. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001;48:62-9. (Pubitemid 32042643)
58. Makela A, Kuusi T, Schroder T. Inhibition of serum phospholipase-A in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Labor Invest 1997;57:401-7. (Pubitemid 27344912)
59. Gross V, Leser HG, Heinisch A, Scholmerich J. Inflammatory mediators and cytokines - new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993;40:522-30. (Pubitemid 24006279)
60. Andren-Sandberg A. Clinical pancreatology I: Pancreatic medical history. N Am J Med Sci 2010;2:502-9.
61. Lankisch PG, Koop H, Winckler K, Kunze H, Vogt W. Indomethacin treatment of acute experimental pancreatitis in the rat. Scand J Gastroenterol 1978;13:629-33. (Pubitemid 9003867)
62. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012;366:1414-22.
63. Ebbehoj N, Friis J, Svendsen LB, Bulow S, Madsen P. Indomethacin treatment of acute pancreatitis. A controlled double-blind trial. Scand J Gastroenterol 1985;20:798-800. (Pubitemid 15015111)
64. Rau B, Poch B, Gansauge F, Bauer A, Nussler AK, Nevalainen T et al. Pathophysiologic role of oxygen free radicals in acute pancreatitis: initiating event or mediator of tissue damage? Ann Surg 2000;231:352-60. (Pubitemid 30137123)
65. Hackert T, Werner J. Antioxidant therapy in acute pancreatitis: experimental and clinical evidence. Antioxid Redox Signal 2011;15:2767-77.
66. Scharer N SP, Deardon D, Lee S, Taylor P, and Braganza JM. Clinical trial of 24 hours treatment with glutathione precursors in acute panreatitis. Clin Drug Investig 1995;10:147-57.
67. Siriwardena AK, Mason JM, Balachandra S, Bagul A, Galloway S, Formela L et al. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut 2007;56:1439-44. (Pubitemid 47517841)
68. Sateesh J, Bhardwaj P, Singh N, Saraya A. Effect of antioxidant therapy on hospital stay and complications in patients with early acute pancreatitis: a randomised controlled trial. Trop Gastroenterol 2009;30:201-6.
69. Mohseni Salehi Monfared SS, Vahidi H, Abdolghaffari AH, Nikfar S, Abdollahi M. Antioxidant therapy in the management of acute, chronic and post-ERCP pancreatitis: a systematic review. World J Gastroenterol 2009;15(36):4481-90.
70. Xue P, Deng LH, Xia Q, Zhang ZD, Hu WM, Yang XN et al. Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage. World J Gastroenterol 2008;14:474-8. (Pubitemid 351320859)
71. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993;176:480-3. (Pubitemid 23138141)
72. Sainio V, Kemppainen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995;346(8976):663-7.
73. Schwartz B, Dowell S. Management of otitis media: the case for more judicious and targeted antibiotic use. HMO Pract 1997;11:139-40.
74. Sharma VK, Howden CW. Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis. Pancreas 2001;22:28-31. (Pubitemid 32046211)
75. Villatoro E, Mulla M, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2010:CD002941.
76. Mounzer R, Langmead CJ, Wu BU, Evans AC, Bishehsari F, Muddana V et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. Gastroenterology 2012;142:1476-82; quiz e15-6.